Cyteir Therapeutics Inc (CYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2009 | 12-2008 | 12-2007 | 12-2006 | 12-2005 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -900 | -197,000 | 207,300 | 195,200 | 60,100 |
| Depreciation Amortization | 159,300 | 139,200 | 145,600 | 152,800 | 168,100 |
| Income taxes - deferred | -41,600 | -17,900 | 27,200 | 15,900 | -24,300 |
| Accounts receivable | 100,300 | 79,500 | -38,800 | -33,600 | -12,900 |
| Accounts payable and accrued liabilities | 17,600 | -49,900 | 2,800 | 15,000 | 2,800 |
| Other Working Capital | 392,400 | -103,700 | -110,300 | -131,700 | -11,000 |
| Other Operating Activity | -61,800 | 380,700 | 36,900 | -12,600 | 49,600 |
| Operating Cash Flow | $565,300 | $230,900 | $270,700 | $201,000 | $232,400 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -175,500 | -180,000 | -114,800 | -102,500 | -105,300 |
| Net Acquisitions | N/A | N/A | N/A | N/A | -1,384,800 |
| Other Investing Activity | -11,400 | -13,400 | 38,700 | 206,600 | 105,500 |
| Investing Cash Flow | $-186,900 | $-193,400 | $-76,100 | $104,100 | $-1,384,600 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -29,900 | -3,000 | -1,200 | 200 | 45,900 |
| Debt Issued | 390,200 | 282,000 | 222,000 | 241,200 | 1,438,400 |
| Debt Repayment | -532,800 | -278,700 | -319,800 | -632,800 | -571,900 |
| Common Stock Issued | 7,400 | 11,200 | 39,300 | 45,000 | 17,700 |
| Common Stock Repurchased | 0 | -46,400 | -77,300 | N/A | N/A |
| Dividend Paid | -9,200 | -24,600 | -19,600 | -18,800 | -17,800 |
| Other Financing Activity | 0 | 5,300 | 11,700 | 10,800 | -6,500 |
| Financing Cash Flow | $-174,300 | $-54,200 | $-144,900 | $-354,400 | $905,800 |
| Exchange Rate Effect | 2,300 | -4,800 | 3,500 | 4,300 | -8,800 |
| Beginning Cash Position | 55,300 | 76,800 | 23,600 | 68,600 | 323,800 |
| End Cash Position | 261,700 | 55,300 | 76,800 | 23,600 | 68,600 |
| Net Cash Flow | $206,400 | $-21,500 | $53,200 | $-45,000 | $-255,200 |
| Free Cash Flow | |||||
| Operating Cash Flow | 565,300 | 230,900 | 270,700 | 201,000 | 232,400 |
| Capital Expenditure | -175,500 | -180,000 | -114,800 | -102,500 | -105,300 |
| Free Cash Flow | 389,800 | 50,900 | 155,900 | 98,500 | 127,100 |